A Study of Eloralintide (LY3841136) in Healthy Participants
← catalyst calendarNCT07701083 · readout ≤ 73 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
58estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: Eloralintide — also filed as LY3841136
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide
measured Predose on Day 1 through Day 57
PK: Maximum Concentration (Cmax) of Eloralintide
measured Predose on Day 1 through Day 57
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed